November 16, 2026
Invivyd Reports Third Quarter 2026 Financial Results and Recent Business Highlights
October 21, 2026
Invivyd Presents VMS063, a Potential Best-in-Class Monoclonal Antibody Candidate for the Treatment and Prevention of Measles, at IDWeek 2026
September 8, 2026
Invivyd to Participate in Upcoming September Investor Conferences
September 3, 2026
Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Displaying 1 - 10 of 36